A early phase II study using 19 personalized peptide vaccines (KRM-19) for metastatic recurrent triple negative breast cancer patients who had been resistant to standard treatment.
Phase 1
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000014616
- Lead Sponsor
- Kurume University School of Medicine Department of Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious complication including active severe infection, circulatory failure, respiratory failure, renal failure, immunodeficiency, blood coagulation disorder etc. 2)Patients with active double cancer. 3)Patients who had a history of serious allergic disease. 4)(Female) pregnant women, lactating women and patients who want to become pregnant. Male breast cancer patients. 5)Other patients who are identified inappropriate patients for this study by the physicians in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Progression free survival time Tumor specific immune response